CUDA 2026 | Professor Lianqu Wang: Leveraging a Century of Medical Education and Regional Healthcare Strengths to Advance Integrated Clinical Care, Education, and Research in Urology at Henan University

CUDA 2026 | Professor Lianqu Wang: Leveraging a Century of Medical Education and Regional Healthcare Strengths to Advance Integrated Clinical Care, Education, and Research in Urology at Henan University

Hosted by the Chinese Medical Doctor Association (CMDA) and the Chinese Urological Association of the CMDA (CUDA), the 2026 CUDA Annual Meeting was held in Zhengzhou, Henan Province, from June 11–14, 2026. The meeting was jointly organized by The First Affiliated Hospital of Zhengzhou University, Henan Provincial People's Hospital, and The First Affiliated Hospital of Henan University, with additional support from Henan Cancer Hospital, The First Affiliated Hospital of Henan University of Chinese Medicine, and The Second Affiliated Hospital of Zhengzhou University.
CUDA 2026 | Professor Linhui Wang: Advancing Precision Kidney-Sparing Surgery in the Modern Era of Renal Cancer Care

CUDA 2026 | Professor Linhui Wang: Advancing Precision Kidney-Sparing Surgery in the Modern Era of Renal Cancer Care

Hosted by the Chinese Medical Doctor Association (CMDA) and the Chinese Urological Association of the CMDA (CUDA), the 2026 CUDA Annual Meeting was held in Zhengzhou, Henan Province, from June 11–14, 2026. Continuing the discipline's mission of "Healthy China, Urology at the Forefront," this year's conference was themed "Collaboration and Innovation for Future Development." The scientific program featured in-depth discussions on precision surgery, advances in minimally invasive techniques, and the evolving role of robotic surgery through expert lectures, live surgical demonstrations, and multidisciplinary forums.
Professor Benlong Yang: Breast Surgery Enters the Era of De-escalation and Individualized Care in Precision Oncology | 2026 CACA Cancer Prevention and Screening Conference

Professor Benlong Yang: Breast Surgery Enters the Era of De-escalation and Individualized Care in Precision Oncology | 2026 CACA Cancer Prevention and Screening Conference

The 2026 CACA Cancer Prevention and Screening Conference recently opened in Hangzhou, bringing together leading oncologists, researchers, and industry experts from across China to discuss advances in cancer prevention, early detection, multidisciplinary collaboration, and translational research. Hosted by the Chinese Anti-Cancer Association (CACA) and its Cancer Prevention and Screening Committee, the meeting aligns with the goals of the Healthy China 2030 initiative by promoting earlier intervention throughout the cancer care continuum.
ASCO China Perspective | Professor Benlong Yang: PREPEC Trial Shows Superior Quality of Life with Prepectoral Breast Reconstruction, but Higher Implant Loss Risk Requires Careful Consideration

ASCO China Perspective | Professor Benlong Yang: PREPEC Trial Shows Superior Quality of Life with Prepectoral Breast Reconstruction, but Higher Implant Loss Risk Requires Careful Consideration

As survival continues to improve for patients with breast cancer, postoperative quality of life (QoL) has become an increasingly important factor in surgical decision-making. Breast reconstruction is an integral component of comprehensive breast cancer care, and the choice of reconstructive technique has a profound impact on long-term functional recovery and psychosocial well-being.
ASCO China Perspective | Professor Yongsheng Wang & Professor Jana de Boniface: Five-Year SENOMAC Results Confirm the Safety of Omitting ALND While Improving Quality of Life, Expanding the Boundaries of Axillary De-escalation

ASCO China Perspective | Professor Yongsheng Wang & Professor Jana de Boniface: Five-Year SENOMAC Results Confirm the Safety of Omitting ALND While Improving Quality of Life, Expanding the Boundaries of Axillary De-escalation

At the 2026 ASCO Annual Meeting, the SENOMAC trial presented its final 5-year overall survival (OS) results together with patient-reported arm morbidity outcomes. The findings further confirmed that, among patients with one or two sentinel lymph nodes containing macrometastases, omission of completion axillary lymph node dissection (ALND) is not only oncologically non-inferior but also significantly improves upper-limb function and lymphedema-related quality of life.
ASCO China Perspective | Professor Kun Wang: Seven-Year KEYNOTE-522 Data Reinforce Curative Potential for High-Risk Early TNBC

ASCO China Perspective | Professor Kun Wang: Seven-Year KEYNOTE-522 Data Reinforce Curative Potential for High-Risk Early TNBC

In the era of chemotherapy alone, patients with high-risk early-stage triple-negative breast cancer (TNBC)—particularly those with node-positive disease or more advanced tumors—continued to face a substantial risk of recurrence after surgery, making cure an ambitious goal for many. Over the past few years, however, immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs) have rapidly moved from the metastatic setting into early-stage treatment, bringing new hope for long-term survival and potential cure.
ASCO China Perspective | Professor Jia Wang and Dr. Hao Yu: “Faster Is Not Always Better”—New Pooled Analysis Reframes Chemotherapy Strategies for High-Risk HR+/HER2− Early Breast Cancer

ASCO China Perspective | Professor Jia Wang and Dr. Hao Yu: “Faster Is Not Always Better”—New Pooled Analysis Reframes Chemotherapy Strategies for High-Risk HR+/HER2− Early Breast Cancer

Perioperative chemotherapy remains a cornerstone of treatment for patients with high-risk HR-positive/HER2-negative early breast cancer. Among the commonly used regimens, dose-dense anthracycline-taxane chemotherapy has long been considered a standard option. However, important clinical questions remain regarding the optimal timing of chemotherapy, patient selection, regimen composition, and treatment intensity.